Phare bio's mission is to develop critically needed antibiotics to address a looming crisis in antibiotic resistance. Using novel ai and deep learning approaches, phare bio aims to rapidly discover and develop new classes of antibiotics against the deadliest pathogens, and ensure that these therapies reach the patients in greatest need.
Phare bio's program mandate is to develop critically needed antibiotics to address a looming crisis in antibiotic resistance. Phare bio has a number of promising early-stage pipeline projects and is conducting extensive in vitro and in vivo drug development studies to advance potential antibiotics through the research and development process. These antibiotic candidates are discovered using novel ai/deep learning methodologies pioneered by professor jim collins' lab at mit (phare bio's co-founder), and are developed and optimized by phare bio for future clinical application. With this cutting-edge platform and a nonprofit business model, phare bio is developing new classes of antibiotics and uniquely addressing economic challenges facing the antibiotic market. In this past year, phare bio discovered and studied additional novel antibiotics with its generative ai drug design platform, further advancing its early-stage pipeline.